14729-D9831C00002- 1 Month Biopsy Study (Biopsy)
A Double-blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Evaluate the Histological Changes, Cellularity, Clinical Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Frieburg, Germania
- Research Site
-
GROßHANSDORF, Germania
- Research Site
-
Hannover, Germania
- Research Site
-
-
-
-
-
Amsterdam, Olanda
- Research Site
-
-
-
-
-
Leicester, Regno Unito
- Research Site
-
London, Regno Unito
- Research Site
-
Manchester, Regno Unito
- Research Site
-
Newcastle upon Tyne, Regno Unito
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Men or women 40 years or above
- FEV1 between 40 and 80% of predicted normal value post-bronchodilator
- Clinical diagnosis of COPD
Exclusion Criteria:
- Other clinically relevant disease or disorders
- Exacerbation of COPD within 30 days
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore placebo: Placebo
|
Placebo
|
|
Sperimentale: AZD1981
|
Oral tablet, twice daily, 4 weeks treatment
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Aggregated Pathology Score
Lasso di tempo: Before and after 1 month treatment
|
Composite endpoint subscores: histological grade, immunohistochemistry grade, leucocyte counts.
Each subscore measured on scale 1 (normal) to 5 (worst outcome).
Composite score summed across the subscores, ranging from 3 (normal) to 15 (worst outcome).
Change from baseline.
|
Before and after 1 month treatment
|
|
Bronchoalveolar Lavage (BAL): Eosinophil Count (%)
Lasso di tempo: Before and after 1 month treatment
|
Change in Bronchoalveolar Lavage (BAL): Eosinophil count (% of total) from baseline
|
Before and after 1 month treatment
|
|
Bronchoalveolar Lavage (BAL): Neutrophil Count (%)
Lasso di tempo: Before and after 1 month treatment
|
Change in Bronchoalveolar Lavage (BAL): Neutrophil count (% of total) from baseline
|
Before and after 1 month treatment
|
|
Bronchoalveolar Lavage (BAL): Macrophages Count (%)
Lasso di tempo: Before and after 1 month treatment
|
Change in Bronchoalveolar Lavage (BAL): Macrophages count (% of total) from baseline
|
Before and after 1 month treatment
|
|
Bronchoalveolar Lavage (BAL): Lymphocytes Count (%)
Lasso di tempo: Before and after 1 month treatment
|
Change in Bronchoalveolar Lavage (BAL): Lymphocytes count (% of total) from baseline
|
Before and after 1 month treatment
|
|
Bronchoalveolar Lavage (BAL): Epithelial Cells Count (%)
Lasso di tempo: Before and after 1 month treatment
|
Change in Bronchoalveolar Lavage (BAL): Epithelial cells count (% of total) from baseline
|
Before and after 1 month treatment
|
|
Bronchoalveolar Lavage (BAL): Total Cells Count
Lasso di tempo: Before and after 1 month treatment
|
Change in Bronchoalveolar Lavage (BAL): Total cells count from baseline
|
Before and after 1 month treatment
|
|
Induced Sputum: Eosinophil Count (%)
Lasso di tempo: Before and after 3 week treatment
|
Change in Induced sputum Eosinophil count (% of total) from baseline
|
Before and after 3 week treatment
|
|
Induced Sputum: Neutrophils Count (%)
Lasso di tempo: Before and after 3 week treatment
|
Change in Induced sputum Neutrophils count (% of total) from baseline
|
Before and after 3 week treatment
|
|
Induced Sputum: Macrophages Count (%)
Lasso di tempo: Before and after 3 week treatment
|
Change in Induced sputum Macrophages count (% of total) from baseline
|
Before and after 3 week treatment
|
|
Induced Sputum: Lymphocytes Count (%)
Lasso di tempo: Before and after 3 week treatment
|
Change in Induced sputum Lymphocytes count (% of total) from baseline
|
Before and after 3 week treatment
|
|
Induced Sputum: Epithelial Cells Count (%)
Lasso di tempo: Before and after 3 week treatment
|
Change in Induced sputum Epithelial cells count (% of total) from baseline
|
Before and after 3 week treatment
|
|
Induced Sputum: Total Cells Count
Lasso di tempo: Before and after 3 week treatment
|
Change in Induced sputum Total cells count from baseline
|
Before and after 3 week treatment
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Forced Expiratory Volume in 1 Second (FEV1)
Lasso di tempo: Before and after 1 month treatment
|
Change in Forced Expiratory Volume in 1 second (FEV1) from baseline to end of treatment
|
Before and after 1 month treatment
|
|
Clinical Chronic Obstructive Pulmonary Disease (COPD) The Clinical COPD Questionnaire (CCQ)
Lasso di tempo: Before and after 1 month treatment
|
Change in total CCQ score from baseline to last measurement on treatment.
scored on a scale of 0 - 6. 0 =(low symptoms)-6 =(high symptoms)
|
Before and after 1 month treatment
|
|
Peak Expiratory Flow (PEF) Morning
Lasso di tempo: Before and after 1 month treatment
|
Mean change in Peak Expiratory Flow (PEF) morning from baseline to the average of the treatment period
|
Before and after 1 month treatment
|
|
Peak Expiratory Flow (PEF) Evening
Lasso di tempo: Before and after 1 month treatment
|
Mean change in Peak Expiratory Flow (PEF) evening from baseline to the average of the treatment period
|
Before and after 1 month treatment
|
|
Chronic Obstructive Pulmonary Disease (COPD) Symptom Night-time Awakenings Score
Lasso di tempo: Before and after 1 month treatment
|
Mean change in COPD symptom night-time awakening score from baseline to the average of the treatment period.
0=(no symptom)-4=(no sleep)
|
Before and after 1 month treatment
|
|
Chronic Obstructive Pulmonary Disease (COPD) Symptom Breathing Score
Lasso di tempo: Before and after 1 month treatment
|
Mean change in COPD symptom breathing score from baseline to the average of the treatment period.
0= (none) - 4 =(severe).
|
Before and after 1 month treatment
|
|
Chronic Obstructive Pulmonary Disease (COPD) Symptom Cough Score
Lasso di tempo: Before and after 1 month treatment
|
Mean change in COPD symptom cough score from baseline to the average of the treatment period.
0= (none) - 4= (almost constant)
|
Before and after 1 month treatment
|
|
Chronic Obstructive Pulmonary Disease (COPD) Symptom Sputum Score
Lasso di tempo: Before and after 1 month treatment
|
Mean change in COPD symptom sputum score from baseline to the average of the treatment period.
0= (none) - 4= (severe).
|
Before and after 1 month treatment
|
|
Adverse Event (AE)
Lasso di tempo: 1 month
|
Number of participants with an Adverse Event
|
1 month
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Norbert Krug, Fraunhofer Institute
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Inizio studio
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- D9831C00002
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .